# Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris

> **NCT01600222** · PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 37 (actual)

## Conditions studied

- Psoriasis Vulgaris

## Interventions

- **DRUG:** LEO 90100

## Key facts

- **NCT ID:** NCT01600222
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01600222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01600222, "Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01600222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*